Bioson Pharmaceutical Reports Q1 Sales of 19.9 Billion Won... "Four Consecutive Quarters of Profit"

Bioson Pharmaceutical announced on the 14th that its consolidated sales for the first quarter of this year reached 19.9 billion KRW, a 45.4% increase compared to the same period last year. Operating profit for the same period was recorded at 700 million KRW.

This quarter, the rapid growth of the Over-The-Counter (OTC) division stood out. The OTC division's sales amounted to 3.2 billion KRW, growing more than 220% compared to the same period last year. The company succeeded in securing new supply channels for OTC products such as ‘Libertain Liquid’, and aggressive sales and marketing efforts through the exclusive supply contract for ‘Lalaola Liquid’ signed with Yuhan Corporation last year significantly contributed to sales growth.

The Ethical Therapeutics (ETC) division also saw sales increase by 37% year-on-year to 10.2 billion KRW. Focusing on sales of high-profit core products resulted in strong sales growth in chronic disease treatments such as Jebica Tablets (hypertension), Atorvastatin Tablets (hyperlipidemia), and Choline Salicylate Tablets (cognitive enhancer). The Alzatin Capsules (gastric ulcer treatment), a nizatidine formulation resold since 2022, also contributed to this strong performance.

Additionally, the Contract Manufacturing Organization (CMO) division recorded sales of 6 billion KRW, marking a 33% growth compared to the same period last year. A company representative stated, “Thanks to the strong sales of key products, we have maintained a profit trend for four consecutive quarters following the turnaround to operating profit on an annual basis last year. Moving forward, we will continue to strengthen our sales competitiveness and maximize production efficiency to focus more on external growth and profitability expansion.”

Meanwhile, Bioson Pharmaceutical is accelerating preparations for the successful domestic commercialization of Onapraju (generic name: Ofiranserin). In April, the two companies signed a Memorandum of Understanding (MOU) with Boryung to discuss cooperation plans for the distribution and sales of Onapraju.